A Phase 1b Study of Vismodegib with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.

Prasse, Antje; Ramaswamy, Murali; Mohan, Shaun; Pan, Lin; Kenwright, Andrew; Neighbors, Margaret; Belloni, Paula; LaCamera, Peter P

Prasse, Antje; Ramaswamy, Murali; Mohan, Shaun; Pan, Lin; Kenwright, Andrew; Neighbors, Margaret; Belloni, Paula; LaCamera, Peter P.

Afiliación

Prasse A; Hannover Medical School and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany. prasse.antje@mh-hannover.de.
Ramaswamy M; PulmonIx, LLC, and Cone Health, Greensboro, NC, USA.
Mohan S; Genentech, Inc., South San Francisco, CA, USA.
Pan L; Genentech, Inc., South San Francisco, CA, USA.
Kenwright A; Genentech, Inc., South San Francisco, CA, USA.
Neighbors M; Genentech, Inc., South San Francisco, CA, USA.
Belloni P; Genentech, Inc., South San Francisco, CA, USA.
LaCamera PP; St. Elizabeth's Medical Center, Boston, MA, USA.

Pulm Ther ; 5(2): 151-163, 2019 Dec.

Article en En | MEDLINE | ID: mdl-32026407

Palabras clave

Hedgehog signaling pathway; Idiopathic pulmonary fibrosis; Pirfenidone; Safety; Tolerability; Vismodegib

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Pulm Ther Año: 2019 Tipo del documento: Article País de afiliación: Alemania

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google